Clinical Blogs

When the COVID-19 pandemic became a serious concern all the way back in March, businesses had to find a way to adapt. Since it is abundantly clear that this is in no way a short-term problem, it is all the more critical to start to look back and analyze some of the data from the earlier months. ...

As claims age, the percentage of spend for prescription drugs increases. Further, as claims age, the likelihood that the injured worker becomes a Medicare beneficiary as a result of age or disability increases. The result, high prescription drug costs allocated in the Medicare Set-Aside (MSA) become...

The opioid epidemic has become a national public health problem. Although, the opioid epidemic is being addressed nationally and drug overdose deaths decreased by 4% from 2017 to 2018, still more than 67,000 people died from drug overdoses in 2018, and almost 70% involved a prescription or illicit opioid....

New Express Scripts Research Examines Americans' Use of Mental Health Medications While COVID-19 makes its monumental mark on the world's health and economy, new research from Express Scripts reveals it is also making a significant impact on our mental health. According to the research, the number...

When I graduated from pharmacy school over forty years ago I had a vision for a future of pharmacy where pharmacists were recognized and compensated for their knowledge of medication as opposed to the dispensing of medication, and I am very proud of the fact that today, at myMatrixx, I have dozens...

The U.S. Food and Drug Administration (FDA) recently released a MedWatch Safety Alert regarding serious concerns around the use of gabapentinoids and the risk of serious breathing problems for patients who have respiratory risk factors, as well as those utilizing opioids or any other medications...

The long and winding road for the drug Embeda® (morphine sulfate and naltrexone hydrochloride) appears to be nearing its end. The manufacturer, Pfizer, has not yet released any public information, but the Food and Drug Administration (FDA) has posted on its website the date of November 15, 2019,...

The Centers for Disease Control and Prevention (CDC) was the first to sound the alarm on the U.S. opioid epidemic. For years, the CDC tracked the epidemic and shared the alarming statistics with the medical community in hopes that it would make an impact, yet opioid overdose deaths continued to rise....

Lyrica was initially approved by the FDA in 2004. Following approval for further indications in 2007 and again in 2012, Lyrica’s patent was finally set to expire at the end of 2018. Since Lyrica is routinely seen as one of the higher spend medications in Workers’...

On April 19, the Food and Drug Administration (FDA) granted final approval of the first generic for naloxone nasal spray, more commonly known as Narcan. Naloxone is an opioid antagonist and this life-saving medication can stop or reverse the effects of an opioid overdose.“In the wake of the opioid...